Published in Nat Nanotechnol on October 23, 2011
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Refilling drug delivery depots through the blood. Proc Natl Acad Sci U S A (2014) 2.10
Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol (2015) 2.08
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano (2012) 1.62
TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A (2012) 1.51
Strategies for advancing cancer nanomedicine. Nat Mater (2013) 1.48
Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett (2014) 1.37
On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better. Sci Rep (2013) 1.35
RNAi therapies: drugging the undruggable. Sci Transl Med (2014) 1.26
Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. ACS Nano (2012) 1.23
Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J Am Chem Soc (2012) 1.22
Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther (2012) 1.19
A smart and versatile theranostic nanomedicine platform based on nanoporphyrin. Nat Commun (2014) 1.17
Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. Nat Commun (2013) 1.16
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA. Mol Ther Nucleic Acids (2012) 1.16
Hybrid nanoparticles for detection and treatment of cancer. Adv Mater (2012) 1.16
Advanced materials and processing for drug delivery: the past and the future. Adv Drug Deliv Rev (2012) 1.14
Investigating the optimal size of anticancer nanomedicine. Proc Natl Acad Sci U S A (2014) 1.13
Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy. Nat Commun (2014) 1.11
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A (2013) 1.08
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther (2012) 1.07
Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano (2013) 1.07
On-demand drug release system for in vivo cancer treatment through self-assembled magnetic nanoparticles. Angew Chem Int Ed Engl (2013) 1.05
Nonporous Silica Nanoparticles for Nanomedicine Application. Nano Today (2013) 1.04
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release (2012) 1.04
PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. Bioconjug Chem (2012) 1.04
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials (2013) 1.04
Translating materials design to the clinic. Nat Mater (2013) 1.03
Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov (2015) 1.02
The Impact of Aspect Ratio on the Biodistribution and Tumor Homing of Rigid Soft-Matter Nanorods. Adv Healthc Mater (2015) 1.01
Photoswitchable nanoparticles for in vivo cancer chemotherapy. Proc Natl Acad Sci U S A (2013) 0.99
Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A (2013) 0.99
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Polymeric Nanostructures for Imaging and Therapy. Chem Rev (2015) 0.99
Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release (2013) 0.97
PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel. Bioconjug Chem (2013) 0.96
Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano (2013) 0.96
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano (2013) 0.96
Biomolecular corona on nanoparticles: a survey of recent literature and its implications in targeted drug delivery. Front Chem (2014) 0.95
Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. ACS Nano (2016) 0.95
Vascular bursts enhance permeability of tumour blood vessels and improve nanoparticle delivery. Nat Nanotechnol (2016) 0.93
3-Helix micelles stabilized by polymer springs. J Am Chem Soc (2012) 0.93
Blood-stable, tumor-adaptable disulfide bonded mPEG-(Cys)4-PDLLA micelles for chemotherapy. Biomaterials (2012) 0.93
Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol Ther (2013) 0.93
Size-dependent tumor penetration and in vivo efficacy of monodisperse drug-silica nanoconjugates. Mol Pharm (2013) 0.93
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev (2013) 0.92
Evaluation of doxorubicin-loaded 3-helix micelles as nanocarriers. Biomacromolecules (2013) 0.92
Ultra-high throughput synthesis of nanoparticles with homogeneous size distribution using a coaxial turbulent jet mixer. ACS Nano (2014) 0.92
Cisplatin-loaded core cross-linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice. Int J Nanomedicine (2012) 0.91
Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer. J Control Release (2015) 0.90
Probing of the assembly structure and dynamics within nanoparticles during interaction with blood proteins. ACS Nano (2012) 0.90
Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. Nanomedicine (2013) 0.90
The nano-plasma interface: Implications of the protein corona. Colloids Surf B Biointerfaces (2014) 0.90
Atherosclerotic plaque targeting mechanism of long-circulating nanoparticles established by multimodal imaging. ACS Nano (2015) 0.90
Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines. Theranostics (2015) 0.89
Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials (2014) 0.89
Photoacoustic imaging enhanced by indocyanine green-conjugated single-wall carbon nanotubes. J Biomed Opt (2013) 0.88
Multimodal in vivo imaging exposes the voyage of nanoparticles in tumor microcirculation. ACS Nano (2013) 0.88
Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett (2015) 0.88
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci U S A (2016) 0.87
Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc Natl Acad Sci U S A (2013) 0.87
Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci U S A (2015) 0.87
A pH-activatable nanoparticle with signal-amplification capabilities for non-invasive imaging of tumour malignancy. Nat Nanotechnol (2016) 0.87
Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol (2013) 0.86
Shrinkage of pegylated and non-pegylated liposomes in serum. Colloids Surf B Biointerfaces (2013) 0.86
Highly efficient hierarchical micelles integrating photothermal therapy and singlet oxygen-synergized chemotherapy for cancer eradication. Theranostics (2014) 0.86
A universal protein tag for delivery of SiRNA-aptamer chimeras. Sci Rep (2013) 0.85
Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release (2013) 0.85
Stimuli-responsive nanoparticles for targeting the tumor microenvironment. J Control Release (2015) 0.85
Advances in Lipid Nanoparticles for siRNA Delivery. Pharmaceutics (2013) 0.85
A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLoS One (2013) 0.85
Recent advances in lymphatic targeted drug delivery system for tumor metastasis. Cancer Biol Med (2014) 0.84
Enhanced penetration into 3D cell culture using two and three layered gold nanoparticles. Int J Nanomedicine (2013) 0.84
Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin. J Control Release (2015) 0.83
Matrix metalloproteinase 2-sensitive multifunctional polymeric micelles for tumor-specific co-delivery of siRNA and hydrophobic drugs. Biomaterials (2014) 0.83
Dual imaging-guided photothermal/photodynamic therapy using micelles. Biomaterials (2014) 0.83
Targeted delivery system of nanobiomaterials in anticancer therapy: from cells to clinics. Biomed Res Int (2014) 0.83
Drug-induced morphology switch in drug delivery systems based on poly(2-oxazoline)s. ACS Nano (2014) 0.83
Factors influencing in vivo disposition of polymeric micelles on multiple administrations. ACS Med Chem Lett (2014) 0.82
Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. J Control Release (2016) 0.82
Fluorescent Polymer Nanoparticles Based on Dyes: Seeking Brighter Tools for Bioimaging. Small (2016) 0.82
Reduction-sensitive dual functional nanomicelles for improved delivery of paclitaxel. Bioconjug Chem (2014) 0.82
Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system. AAPS J (2014) 0.82
Magneto-optical nanoparticles for cyclic magnetomotive photoacoustic imaging. ACS Nano (2015) 0.82
Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy. Nat Commun (2016) 0.81
Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip. J Control Release (2014) 0.81
Thermally responsive nanoparticle-encapsulated curcumin and its combination with mild hyperthermia for enhanced cancer cell destruction. Acta Biomater (2014) 0.81
Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials (2015) 0.81
Folic-acid-conjugated pullulan/poly(DL-lactide-co-glycolide) graft copolymer nanoparticles for folate-receptor-mediated drug delivery. Nanoscale Res Lett (2015) 0.81
Site-Specific Drug-Releasing Polypeptide Nanocarriers Based on Dual-pH Response for Enhanced Therapeutic Efficacy against Drug-Resistant Tumors. Theranostics (2015) 0.81
3D Porous Chitosan-Alginate Scaffolds as an In Vitro Model for Evaluating Nanoparticle-Mediated Tumor Targeting and Gene Delivery to Prostate Cancer. Biomacromolecules (2015) 0.81
Biological interactions of carbon-based nanomaterials: From coronation to degradation. Nanomedicine (2015) 0.81
PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel. Mol Pharm (2014) 0.81
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol (2016) 0.80
Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif. Biomacromolecules (2014) 0.80
Quantifying uncertainties in the microvascular transport of nanoparticles. Biomech Model Mechanobiol (2013) 0.80
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol (2005) 9.70
The dawning era of polymer therapeutics. Nat Rev Drug Discov (2003) 7.86
Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm (2008) 7.67
Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat Mater (2008) 4.81
Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev (2001) 4.52
Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett (2009) 4.45
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst (2006) 4.27
Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther (2006) 2.48
Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res (2003) 2.47
Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci U S A (2007) 2.30
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol (1998) 2.12
Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol (2005) 2.09
Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res (1996) 2.00
Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci (2009) 1.88
Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. Bioconjug Chem (2005) 1.82
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer (2004) 1.67
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br J Cancer (2011) 1.44
Polymeric micelles for drug delivery. Expert Opin Drug Deliv (2006) 1.35
Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinum(II) in the core. J Control Release (2001) 1.29
Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med (2011) 1.26
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer (2008) 1.23
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev (2010) 1.16
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci (2008) 1.10
Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release (2005) 1.08
Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity. J Control Release (2007) 1.02
Direct and instantaneous observation of intravenously injected substances using intravital confocal micro-videography. Biomed Opt Express (2010) 0.98
Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev (1999) 0.90
A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol (1980) 113.75
Evolutionary rate at the molecular level. Nature (1968) 33.15
The number of heterozygous nucleotide sites maintained in a finite population due to steady flux of mutations. Genetics (1969) 22.59
TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature (1997) 15.75
A model of mutation appropriate to estimate the number of electrophoretically detectable alleles in a finite population. Genet Res (1973) 13.08
Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science (1997) 9.53
Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J (1998) 9.36
A stochastic model concerning the maintenance of genetic variability in quantitative characters. Proc Natl Acad Sci U S A (1965) 9.20
Obesity, cigarette smoking, and telomere length in women. Lancet (2005) 8.59
Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38
Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 7.86
Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 7.72
The substitutional load in a finite population. Heredity (Edinb) (1969) 7.56
Preliminary criteria for classification of adult Still's disease. J Rheumatol (1992) 7.53
Linkage disequilibrium at steady state determined by random genetic drift and recurrent mutation. Genetics (1969) 7.33
Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature (2001) 7.31
Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature (1998) 7.30
Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science (1999) 7.12
The effects of social status on biological aging as measured by white-blood-cell telomere length. Aging Cell (2006) 6.80
Protein polymorphism as a phase of molecular evolution. Nature (1971) 6.68
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Theoretical foundation of population genetics at the molecular level. Theor Popul Biol (1971) 6.38
Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science (2000) 6.22
A novel integron-like element carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother (1995) 6.00
The probability of consanguineous marriages. Genetics (1966) 5.85
Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science (2000) 5.62
Estimation of evolutionary distances between homologous nucleotide sequences. Proc Natl Acad Sci U S A (1981) 5.34
ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep (2001) 5.32
On the stochastic model for estimation of mutational distance between homologous proteins. J Mol Evol (1972) 5.16
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
On some principles governing molecular evolution. Proc Natl Acad Sci U S A (1974) 4.97
Multilayer white light-emitting organic electroluminescent device. Science (1995) 4.86
Genetic variability maintained in a finite population due to mutational production of neutral and nearly neutral isoalleles. Genet Res (1968) 4.83
The rate of molecular evolution considered from the standpoint of population genetics. Proc Natl Acad Sci U S A (1969) 4.75
Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med (2001) 4.71
Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science (1999) 4.69
Pattern of neutral polymorphism in a geographically structured population. Genet Res (1971) 4.65
On the constancy of the evolutionary rate of cistrons. J Mol Evol (1971) 4.49
TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J (1997) 4.48
The age of a neutral mutant persisting in a finite population. Genetics (1973) 4.44
Genetic variability and effective population size when local extinction and recolonization of subpopulations are frequent. Proc Natl Acad Sci U S A (1980) 4.37
Smad6 inhibits signalling by the TGF-beta superfamily. Nature (1997) 4.34
The basal ganglia and adaptive motor control. Science (1994) 4.27
Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem (2001) 4.22
Regulation of transcription by dimerization of erythroid factor NF-E2 p45 with small Maf proteins. Nature (1994) 4.20
Reciprocal subsidies: dynamic interdependence between terrestrial and aquatic food webs. Proc Natl Acad Sci U S A (2001) 4.13
Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A (2000) 4.08
Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension (2001) 4.07
Preponderance of synonymous changes as evidence for the neutral theory of molecular evolution. Nature (1977) 4.00
ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell (1998) 3.98
Development of a pertussis component vaccine in Japan. Lancet (1984) 3.94
Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol (1989) 3.89
Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (1989) 3.80
Distribution of allelic frequencies in a finite population under stepwise production of neutral alleles. Proc Natl Acad Sci U S A (1975) 3.64
Cloning of a TGF beta type I receptor that forms a heteromeric complex with the TGF beta type II receptor. Cell (1993) 3.57
Linkage disequilibrium between two segregating nucleotide sites under the steady flux of mutations in a finite population. Genetics (1971) 3.51
Ceftizoxime (FK 749), a new parenteral cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother (1979) 3.51
The average number of generations until extinction of an individual mutant gene in a finite population. Genetics (1969) 3.49
Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. J Biol Chem (1994) 3.49
Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell (2006) 3.44
Effect of overall phenotypic selection on genetic change at individual loci. Proc Natl Acad Sci U S A (1978) 3.41
In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrob Agents Chemother (1984) 3.35
The quaking gene product necessary in embryogenesis and myelination combines features of RNA binding and signal transduction proteins. Nat Genet (1996) 3.35
Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension (2000) 3.32
Stepwise mutation model and distribution of allelic frequencies in a finite population. Proc Natl Acad Sci U S A (1978) 3.29
Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell (1999) 3.27
Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J (1999) 3.22
Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem (2000) 2.99
Characterization of type I receptors for transforming growth factor-beta and activin. Science (1994) 2.94
Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev (1995) 2.92
Mutation and evolution at the molecular level. Genetics (1973) 2.79
Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem (1996) 2.77
BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet (1996) 2.75
Gallbladder muscle dysfunction in patients with chronic acalculous disease. Gastroenterology (2001) 2.73
Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res (1998) 2.63
Do rehabilitative nursing homes improve the outcomes of care? J Am Geriatr Soc (1996) 2.63
Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev (1998) 2.56
Polymicrogyria is an uncommon manifestation in 22q11.2 deletion syndrome. Am J Med Genet (2000) 2.54
Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol Cell Biol (1992) 2.53
Fixation of a deleterious allele at one of two "duplicate" loci by mutation pressure and random drift. Proc Natl Acad Sci U S A (1979) 2.51
Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol (2001) 2.51
Role of nonimmune IgG bound to PfEMP1 in placental malaria. Science (2001) 2.50
Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest (1999) 2.50
Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem (2000) 2.47
TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell (1990) 2.46
Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem (1999) 2.44
Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem (1996) 2.43
Murine homolog of SALL1 is essential for ureteric bud invasion in kidney development. Development (2001) 2.42
BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol (2000) 2.40
Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J (1990) 2.38
STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med (1999) 2.36
Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol (1995) 2.36
Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology (2005) 2.33
The common SCN5A mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel. J Med Genet (2004) 2.33
c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. J Biol Chem (1999) 2.32
The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab (1995) 2.32
Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol (2000) 2.32
A RUNX2/PEBP2alpha A/CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci U S A (2000) 2.31
Spectral response curves of single cones in the carp. Vision Res (1967) 2.30